Investigational Drug Combination Could Address Unmet Need in TP53-Positive MDS
The phase 3 trial evaluating eprenetapopt plus Vidaza completed enrollment recently, and could lead to a new standard of care with positive results, according to Dr. Guillermo Garcia-Manero.
Read More